The case against the routine use of radiation therapy in advanced-stage Hodgkin's disease

Cancer Investigation

Volumn 14, Issue 4, 1996, Pages 353-360

  Longo, Dan L ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT;

CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; HEART INFARCTION; HODGKIN DISEASE; PRIORITY JOURNAL; REVIEW; SECOND CANCER;

EID: 0030011656     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609012163     Document Type: Review

References (49)

1. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989.
2. Mauch P, Goodman R, Hellman S: The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42:1039-1045, 1978.
3. Prosnitz LR, Curtis AM, Knowlton AH, et al: Supradiaphragmatic Hodgkin's disease: Significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6:809-813, 1980.
4. Fuller LM, Madoc-Jones H, Hagemeister FB, et al: Further follow up results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: Significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys 6:799-808, 1980.
5. Lee CKK, Bloomfield CD, Goldman AI, et al: Prognostic significance of mediastinal involvement in Hodgkin' s disease treated with curative radiotherapy. Cancer 46:2403-2409, 1980.
6. Hoppe RT, Coleman CN, Cox RS, et al: The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 59:455-465, 1982.
7. Behar RA, Horning SJ, Hoppe RT: Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 25:771-776, 1993.
8. Longo DL, Glatstein E, Duffey PL, et al: Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven year results of a prospective randomized trial. J Clin Oncol 9:906-917, 1991.
9. Ekert H, Waters KD, Smith PJ, et al: Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. J Clin Oncol 6:1845-1850, 1988.
10. Longo DL, Russo A, Duffey PL, et al: Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment. J Clin Oncol 9:227-235, 1991.
11. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992.
12. Fabian C, Dahlberg S, Miller T, et al: Efficacy of low dose involved field (LDIF) XRT in producing and maintaining CR following PR induction with MOP-BAP chemotherapy in Hodgkin's disease: Results of Southwest Oncology Group study 7808. Proc Am Soc Clin Oncol 8:253, 1989 (abstract 987).
13. Vose J, Armitage J, Weisenburger D, et al: ChlVPP-An effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease. Am J Clin Oncol 11:423-426, 1988.
14. Klimo P, Connors JM: An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 25(Suppl 2):34-40, 1988.
15. O'Reilly SE, Hoskins P, Klimo P, et al: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 2(Suppl 1):17-23, 1991.
16. Fischer JJ, Papac RJ: Theoretical considerations in combinations of localized and systemic therapy for neoplastic diseases. J Theor Biol 37:105-114, 1972.
17. Frei E III, Luce JK, Gamble JF, et al: Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission. Ann Intern Med 79:376-382, 1973.
18. Young RC, Canellos GP, Chabner BA, et al: Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 42:1001-1007, 1978.
19. Prosnitz LR, Farber LR, Kapp DS, et al: Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol 6:603-612, 1988.
20. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986.
21. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 5:742-749, 1987.
22. Hudson MM, Greenwald C, Thompson E, et al: Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11:100-108, 1993.
23. Brizel DM, Winer EP, Prosnitz LR, et al: Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 19:535-542, 1990.
24. Yahalom J, Ryu J, Straus DJ, et al: Impact of adjuvant radiation on the patterns and rale of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 9:2193-2201, 1991.
25. Pavlovsky S, Santarelli MT, Sackmann Muriel F, et al: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A and B Hodgkin's disease. Ann Oncol 3:533-537, 1992.
26. Crowther D, Wagstaff J, Deakin D, et al: A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. J Clin Oncol 2:892-897, 1984.
27. Glick J, Rubin P, Tsiatis A, et al: Hodgkin's disease stage IIIB and IV: Failure of radiation consolidation to improve survival compared to B-MOPP/ABVD: An ECOG study. Proc Am Soc Ther Radiat Oncol 13(Suppl 1):91, 1987 (abstract).
28. Glick J, Tsiatis A, Chen M, et al: Improved survival with MOPP-ABVD compared to BCVPP ± radiotherapy (RT) for advanced Hodgkin's disease: 6-year ECOG results. Blood 76(Suppl 1):350a, 1990 (abstract 1392).
29. Grozea PN, Depersio EJ, Coltman CA Jr, et al: Chemotherapy alone versus combined modality therapy for stage III Hodgkin's disease: A five-year follow-up of a Southwest Oncology group study. In: Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances, edited by F. Cavalli, G Bonadonna, M Rozencweig, Boston, Martinus Nijhoff Publishers, 1985, pp 345-351.
30. Fabian CJ, Mansfield CM, Dahlberg S, et al: Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group randomized study. Ann Intern Med 120:903-912, 1994.
31. Yelle L, Bergsagel D, Basco V, et al: Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada clinical trials group multicenter clinical trial. J Clin Oncol 9:1983-1993, 1991.
32. Diehl V, Pfreundschuh M, Löffler M, et al: Chemotherapy vs. involved-field (IF) radiotherapy for consolidation of remission achieved with three double cycles of cyclophosphamide, vincristine, procarbazine, prednisone (COPP) and doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) for stages IIIB/IV Hodgkin's disease: A randomized trial of the German Hodgkin Study Group. Proc Am Soc Clin Oncol 9:273, 1990 (abstract 1057).
33. Longo DL, Young RC, DeVita VT Jr: Chemotherapy for Hodgkin's disease: The remaining challenges. Cancer Treat Rep 66:925-936, 1982.
34. Kaplan HS: Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 26:1221-1224, 1966.
35. Prosnitz LR: Hodgkin's disease: The right dose. Int J Radiat Oncol Biol Phys 19:803-804, 1990.
36. Schewe KL, Reavis J, Kun LE, et al: Total dose, fraction size, and tumor volume in the local control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 15:25-28, 1988.
37. Vijayakumar S, Myrianthopoulos LC: An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 24:1-13, 1992.
38. Loeffler M, Ruhl U, Hasenclever D, et al: Irradiation with 20, 30 or 40 Gy is equally effective in non-bulky areas after two double cycles of COPP-ABVD polychemotherapy in intermediate stage Hodgkin's disease. Blood 84(Suppl 1):234a, 1994 (abstract 921).
39. Maity A, Goldwein JW, Lange B, et al: Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease: An analysis of the experience at the Children's Hospital of Philadelphia and the Hospital of the University of Pennsylvania. J Clin Oncol 10:929-935, 1992.
40. Lavey RS, Eby NL, Prosnitz LR: Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer 66:80-88, 1990.
41. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988.
42. Blayney DW, Longo DL, Young RC, et al: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 316:710-714, 1987.
43. Valagussa P, Santoro A, Fossati-Bellani F, et al: Sound acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837, 1986.
44. Andrieu JM, Ifrah N, Payen C, et al: Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148-1154, 1990.
45. Van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994.
46. Meadows AT, Obringer AC, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477-484, 1989.
47. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 85:25-31, 1993.
48. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolecents. J Clin Oncol 11:1208-1215, 1993.
49. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949-1955, 1993.